Megan A Coughlin1, Nicole L Werner2, Robert Gajarski3, Samir Gadepalli2, Ronald Hirschl2, John Barks4, Marjorie C Treadwell5, Maria Ladino-Torres6, Jeannie Kreutzman2, George B Mychaliska2. 1. Section of Pediatric Surgery, Department of Surgery, The University of Michigan Medical School, C.S. Mott Children's Hospital, and the Fetal Diagnosis and Treatment Center, Ann Arbor, MI. Electronic address: meganac@med.umich.edu. 2. Section of Pediatric Surgery, Department of Surgery, The University of Michigan Medical School, C.S. Mott Children's Hospital, and the Fetal Diagnosis and Treatment Center, Ann Arbor, MI. 3. Division of Pediatric Cardiology, The University of Michigan Medical School, C.S. Mott Children's Hospital, and the Fetal Diagnosis and Treatment Center, Ann Arbor, MI. 4. Division of Neonatology, The University of Michigan Medical School, C.S. Mott Children's Hospital, and the Fetal Diagnosis and Treatment Center, Ann Arbor, MI. 5. Division of Maternal Fetal Medicine, The University of Michigan Medical School, C.S. Mott Children's Hospital, and the Fetal Diagnosis and Treatment Center, Ann Arbor, MI. 6. Division of Pediatric Radiology, The University of Michigan Medical School, C.S. Mott Children's Hospital, and the Fetal Diagnosis and Treatment Center, Ann Arbor, MI.
Abstract
PURPOSE: This study sought to evaluate prenatal markers' ability to predict severe congenital diaphragmatic hernia(CDH) and assess this subgroup's morbidity and mortality. METHODS: A retrospective review was performed between 2006 and 2014. Prenatal criteria for severe CDH included: liver herniation, lung-to-head ratio (LHR) <1 on prenatal ultrasound and/or observed-to-expected LHR (o/eLHR) <25%, and/or observed-to-expected total lung volume (o/eTLV) <25% on fetal MRI. Postnatal characteristics included: mortality, ECMO utilization, patch closure, persistent suprasystemic pulmonary hypertension (PHtn), O2 requirement at discharge, and few ventilator-free days in the first 60. Statistics performed used unpaired t-test, p<0.05 significant. RESULTS: Overall, 47.5%(29/61) of patients with prenatally diagnosed, isolated CDH met severe criteria. Mean LHR: 1.04±0.35, o/eLHR: 31±10% and o/eTLV: 20±7%. Distribution was 72% LCDH, 24% R-CDH. Overall survival: 38%. ECMO requirement: 92%. Patch rate: 91%. Mean ventilator-free days in 60: 7.1±14. Supplemental oxygen at discharge was required in 27%. In this prenatally diagnosed severe cohort, 58%(15/26) had persistent PHtn post-ECMO requiring inhaled nitric oxide±epoprostenol. Comparing patients with and without PHtn: mean ECMO duration 18±10 days versus 9±7 days (p=0.01) and survival 20% versus 72% (p=0.006). CONCLUSION: A combination of prenatal markers accurately identified severe CDH patients. Outcomes of this group remain poor and persistent PHtn contributes significantly to mortality.
PURPOSE: This study sought to evaluate prenatal markers' ability to predict severe congenital diaphragmatic hernia(CDH) and assess this subgroup's morbidity and mortality. METHODS: A retrospective review was performed between 2006 and 2014. Prenatal criteria for severe CDH included: liver herniation, lung-to-head ratio (LHR) <1 on prenatal ultrasound and/or observed-to-expected LHR (o/eLHR) <25%, and/or observed-to-expected total lung volume (o/eTLV) <25% on fetal MRI. Postnatal characteristics included: mortality, ECMO utilization, patch closure, persistent suprasystemic pulmonary hypertension (PHtn), O2 requirement at discharge, and few ventilator-free days in the first 60. Statistics performed used unpaired t-test, p<0.05 significant. RESULTS: Overall, 47.5%(29/61) of patients with prenatally diagnosed, isolated CDH met severe criteria. Mean LHR: 1.04±0.35, o/eLHR: 31±10% and o/eTLV: 20±7%. Distribution was 72% LCDH, 24% R-CDH. Overall survival: 38%. ECMO requirement: 92%. Patch rate: 91%. Mean ventilator-free days in 60: 7.1±14. Supplemental oxygen at discharge was required in 27%. In this prenatally diagnosed severe cohort, 58%(15/26) had persistent PHtn post-ECMO requiring inhaled nitric oxide±epoprostenol. Comparing patients with and without PHtn: mean ECMO duration 18±10 days versus 9±7 days (p=0.01) and survival 20% versus 72% (p=0.006). CONCLUSION: A combination of prenatal markers accurately identified severe CDHpatients. Outcomes of this group remain poor and persistent PHtn contributes significantly to mortality.
Authors: Jose Luis Peiro; Marc Oria; Emrah Aydin; Rashika Joshi; Nichole Cabanas; Ronny Schmidt; Christoph Schroeder; Mario Marotta; Brian M Varisco Journal: Am J Physiol Lung Cell Mol Physiol Date: 2018-09-27 Impact factor: 5.464
Authors: David J McCulley; Mark D Wienhold; Elizabeth A Hines; Timothy A Hacker; Allison Rogers; Ryan J Pewowaruk; Rediet Zewdu; Naomi C Chesler; Licia Selleri; Xin Sun Journal: J Clin Invest Date: 2017-12-18 Impact factor: 14.808
Authors: Arin L Madenci; Joseph T Church; Robert J Gajarski; Kathryn Marchetti; Edwin J Klein; Megan A Coughlin; Jeannie Kreutzmann; Marjorie Treadwell; Maria Ladino-Torres; George B Mychaliska Journal: Eur J Pediatr Surg Date: 2017-10-16 Impact factor: 2.191
Authors: Brian M Varisco; Lourenco Sbragia; Jing Chen; Federico Scorletti; Rashika Joshi; Hector R Wong; Rebecca Lopes-Figueira; Marc Oria; Jose Peiro Journal: Mol Med Date: 2016-07-19 Impact factor: 6.354
Authors: Sarah J Ullrich; Mollie Freedman-Weiss; Samantha Ahle; Hanna K Mandl; Alexandra S Piotrowski-Daspit; Katherine Roberts; Nicholas Yung; Nathan Maassel; Tory Bauer-Pisani; Adele S Ricciardi; Marie E Egan; Peter M Glazer; W Mark Saltzman; David H Stitelman Journal: Acta Biomater Date: 2021-01-21 Impact factor: 8.947